Exact Mass: 351.19803740000003

Exact Mass Matches: 351.19803740000003

Found 48 metabolites which its exact mass value is equals to given mass value 351.19803740000003, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Tryprostatin B

(3S-trans)-Hexahydro-3-[[2-(3-methyl-2-butenyl)-1H-indol-3-yl]methyl]-pyrrolo[1,2-a]pyrazine-1,4-dione

C21H25N3O2 (351.194667)


A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a prenyl group. CONFIDENCE Penicillium amphipolaria

   

Dipivefrin

2-[(2,2-dimethylpropanoyl)oxy]-5-[1-hydroxy-2-(methylamino)ethyl]phenyl 2,2-dimethylpropanoate

C19H29NO5 (351.20456240000004)


Dipivefrin is only found in individuals that have used or taken this drug. It is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops). Dipivefrin is a prodrug with little or no pharmacologically activity until it is hydrolyzed into epinephrine inside the human eye. The liberated epinephrine, an adrenergic agonist, appears to exert its action by stimulating α- and/or β2-adrenergic receptors, leading to a decrease in aqueous production and an enhancement of outflow facility. The dipivefrin prodrug delivery system is a more efficient way of delivering the therapeutic effects of epinephrine, with fewer side effects than are associated with conventional epinephrine therapy. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EA - Sympathomimetics in glaucoma therapy D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent

   

deoxybrevianamide E

L-Prolyl-2-(1,1-dimethylallyl)-L-tryptophan anhydride

C21H25N3O2 (351.194667)


A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a 1,1-dimethylallyl group.

   

6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide

6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide

C21H25N3O2 (351.194667)


GSK189254A (GSK189254 free base) is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.

   

2-Amino-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3,6-dimethyl-5H-pyrimidin-4-one

2-amino-6-(2-{3-methoxy-[1,1-biphenyl]-3-yl}ethyl)-3,6-dimethyl-3,4,5,6-tetrahydropyrimidin-4-one

C21H25N3O2 (351.194667)


   

Benzeneacetic acid, 4-(2-(diethylamino)-2-oxoethoxy)-3-ethoxy-, propyl ester

Benzeneacetic acid, 4-(2-(diethylamino)-2-oxoethoxy)-3-ethoxy-, propyl ester

C19H29NO5 (351.20456240000004)


   

N-[1-[4-[(4-Pyrimidin-2-ylpiperazin-1-yl)methyl]phenyl]cyclopropyl]acetamide

N-[1-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]methyl}phenyl)cyclopropyl]ethanimidate

C20H25N5O (351.2059)


   
   

Stemonidine

8-methoxy-3-methyl-3-(4-methyl-5-oxooxolan-2-yl)spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5-oxolane]-2-one

C19H29NO5 (351.20456240000004)


CID 5250922 is a natural product found in Stemona japonica with data available.

   
   
   

N,N-Dimethylnaamine D

N,N-Dimethylnaamine D

C21H25N3O2 (351.194667)


   

22N-Tetrahydroalstonin|4-methyl-3,4,4a,5,7,8,13,13b,14,14a-decahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid ethyl ester

22N-Tetrahydroalstonin|4-methyl-3,4,4a,5,7,8,13,13b,14,14a-decahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid ethyl ester

C21H25N3O2 (351.194667)


   

3-[1-(3-methyl-but-2-enyl)-indol-3-ylmethyl]-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione|cyclo(N-prenyl-L-tryptophyl-L-prolyl)|Cyclo-L-prolyl-L-|N-prenyl-cyclo-L-tryptophyl-L-proline

3-[1-(3-methyl-but-2-enyl)-indol-3-ylmethyl]-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione|cyclo(N-prenyl-L-tryptophyl-L-prolyl)|Cyclo-L-prolyl-L-|N-prenyl-cyclo-L-tryptophyl-L-proline

C21H25N3O2 (351.194667)


   
   
   

(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-methylbutanoic acid

(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-methylbutanoic acid

C16H25N5O4 (351.190645)


   
   
   
   
   

4-{2-[3-(2-Furyl)phenyl]ethyl}-6-(3-methylbutoxy)-2-pyrimidinamin e

4-{2-[3-(2-Furyl)phenyl]ethyl}-6-(3-methylbutoxy)-2-pyrimidinamin e

C21H25N3O2 (351.194667)


   

TERT-BUTYL ((S)-1-((S)-2-CARBAMOYLPYRROLIDIN-1-YL)-3-(1H-IMIDAZOL-4-YL)-1-OXOPROPAN-2-YL)CARBAMATE

TERT-BUTYL ((S)-1-((S)-2-CARBAMOYLPYRROLIDIN-1-YL)-3-(1H-IMIDAZOL-4-YL)-1-OXOPROPAN-2-YL)CARBAMATE

C16H25N5O4 (351.190645)


   

Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-cyclohexyl- (9CI)

Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-cyclohexyl- (9CI)

C20H25N5O (351.2059)


   

3-(2,2-DIETHOXY-ETHOXY)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER

3-(2,2-DIETHOXY-ETHOXY)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER

C19H29NO5 (351.20456240000004)


   
   

Sodium lauroyl glutamate

Sodium lauroyl glutamate

C17H30NNaO5 (351.202157)


   

Bisegliptin

Bisegliptin

C18H26FN3O3 (351.1958098)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   
   

D-Phenylalanyl-N-Benzyl-L-Prolinamide

D-Phenylalanyl-N-Benzyl-L-Prolinamide

C21H25N3O2 (351.194667)


   

(6r)-2-Amino-6-[2-(3-Methoxybiphenyl-3-Yl)ethyl]-3,6-Dimethyl-5,6-Dihydropyrimidin-4(3h)-One

(6r)-2-Amino-6-[2-(3-Methoxybiphenyl-3-Yl)ethyl]-3,6-Dimethyl-5,6-Dihydropyrimidin-4(3h)-One

C21H25N3O2 (351.194667)


   

N-(3-allyl-2-hydroxybenzylidene)-4-[(4-methylphenyl)amino]butanohydrazide

N-(3-allyl-2-hydroxybenzylidene)-4-[(4-methylphenyl)amino]butanohydrazide

C21H25N3O2 (351.194667)


   

N-{4-[4-(2-methylbenzoyl)-1-piperazinyl]phenyl}propanamide

N-{4-[4-(2-methylbenzoyl)-1-piperazinyl]phenyl}propanamide

C21H25N3O2 (351.194667)


   

6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine

6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine

C20H25N5O (351.2059)


   
   
   
   

N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine

N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine

C21H25N3O2 (351.194667)


   

N-(9-ethyl-3-carbazolyl)-2-(2-oxolanylmethylamino)acetamide

N-(9-ethyl-3-carbazolyl)-2-(2-oxolanylmethylamino)acetamide

C21H25N3O2 (351.194667)


   
   
   

1-[Diethyl[(E)-2-phenylethenyl]silyl]-2-(diethylsilyl)benzene

1-[Diethyl[(E)-2-phenylethenyl]silyl]-2-(diethylsilyl)benzene

C22H31Si2 (351.1964186)


   

dipivefrin

dipivefrin

C19H29NO5 (351.20456240000004)


S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EA - Sympathomimetics in glaucoma therapy D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent

   
   
   

NPY5RA-972

NPY5RA-972

C21H25N3O2 (351.194667)


NPY5RA-972 is an orally active, central nervous system (CNS) penetrating, potent and selective NPY Y5 receptor antagonist that prevents feeding driven by activation of this receptor[1].